Navigation Links
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
Date:6/8/2009

t-Batar, A., and Minnasch, P.

Method

Responder analysis of at least 1-point improvement from baseline to week 4 on the Disability Assessment Scale [DAS] for the primary therapeutic target after injection of a 20 U/mL dilution or 50 U/mL dilution was evaluated. After injection, observation over a 12-week period was followed by 8 weeks safety follow-up. Botulinum neurotoxin doses were derived from the recommendations from the organization WE MOVE. The individual injection pattern was adapted to patient's needs. A two-sided 95% Newcombe-Wilson confidence interval [CI] for the difference between groups was calculated.

Results

192 patients with upper limb spasticity caused by either stroke (88%), brain injury (5.7%), multiple sclerosis (0.5%) or cerebral palsy (1.6%) were randomized to the 50 U/mL dilution group (95 patients) or to the 20 U/mL dilution group (97 patients). Limb position (60.4%), Dressing (24.0%), Hygiene (9.4%) and Pain (6.3%) were chosen as primary therapeutic target on the DAS. The maximum injected total dose was 495 units NT 201. Four weeks after injection 57.1% of patients had an at least 1-point DAS reduction from the baseline score for their primary therapeutic target. No dilution group was inferior to each other regarding efficacy. 79.9% of patients and 89.0% of investigators reported an improvement in global assessment of efficacy at week 4. There were no relevant differences regarding safety between groups.

About Merz

Merz (KGAa) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in research and development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic dermatology, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fi
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
2. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
3. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
10. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
11. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 TB ... and developing better, faster and affordable treatments, announced ... Senior Vice President, External Affairs. Mr. Brock comes ... Head of Major Donor Relations for WWF International ... his role, Mr. Brock will guide the TB ...
(Date:7/31/2014)... und KISSING, Deutschland, 31. Juli ... und Distributor eines computerunterstützten („robotischen") Koloskopie-Systems für ... (Homi) Shamir , ein weltweit anerkannter Manager ... und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener globaler Visionär ...
(Date:7/31/2014)... , July 31, 2014 Nutrastar International ... producer and supplier of premium branded consumer products, including ... and specialty foods, today announced the signing of its ... and its expansion to Hubei Province ... Central China . ...
Breaking Medicine Technology:TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... Feb. 9, 2011 Reportlinker.com announces that a ... catalogue: European Market for Dental ... http://www.reportlinker.com/p0377961/European-Market-for-Dental-Prosthetics-and-CAD/CAM-Devices-2011.html In 2010, ... crowns, bridges and dentures, were valued at over ...
... 2011 Protect Pharmaceutical Corporation (OTC Bulletin Board: ... of two patents and patents-applications to Grunenthal GmbH, a German ... discovery and research. The patent portfolio includes innovative pain drugs ... Ram Sesha, Protect,s Chief Operating Officer, said, "We are ...
Cached Medicine Technology:Reportlinker Adds European Market for Dental Prosthetics and CAD/CAM Devices 2011 2Protect Pharma Sells Patent Portfolio to Grunenthal GmbH 2
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... By Randy Dotinga ... -- The parasite that causes malaria is growing increasingly resistant ... new surveillance reports. But several new drugs are in development, ... new hope against this global killer. "Although there has ... the battle against malaria is far from won, and there ...
(Date:7/31/2014)... -- Recovery time after surgery may be reduced for ... to a new study. The study,s Irish researchers ... response, reducing the amount of time surgical patients, wounds ... true among people who tend to have healing complications. ... prescribed medications in the world. While they are typically ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... launched a new online reputation management service named ... as well as organizations get rid of Pissed ... the result of extensive research. ReputationChief.Com management assigned ... service for those who are struggling in their ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... Certified Internet Marketing Company, has introduced a new ... quite affordable.     , Ethane Web Technologies has designed ... the expectations of clients and Java Development service ... has given the company a confidence to promise ...
Breaking Medicine News(10 mins):Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 2Health News:Malaria Growing Resistant to Drugs Used to Fight It 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2
... Biosciences LLC, a Boston-based company conceived in partnership ... today that Johnson & Johnson has joined the ... will have the opportunity to invest in the ... to fundamentally transform drug discovery and development and ...
... Limited (Nasdaq: WCRX ) announced today that ... close on Tuesday, January 27, 2009. In addition to ... Executive Officer and Paul Herendeen, Executive Vice President and ... audio webcast to discuss the 2009 Financial Guidance for ...
... Keystone Symposium - Obesity: Novel Aspects of the Regulation ... Genetics, Inc. (NYSE Alternext US: ILI) announced today that ... role genetics play in an individual,s ability to lose ... during tomorrow,s Keystone Symposium titled, "Obesity: Novel Aspects of ...
... Blood Bank is honored to announce that it has ... of Cellular Therapy ("FACT"). CORD:USE is a leading ... processing, storage and distribution of donated cord blood. ... more than 14,000 patients with over 70 life-threatening diseases ...
... DIEGO, Jan. 22 Aero Financial, Inc, a strategic ... that the company has been retained as a strategic ... distributor of natural health information and nutrition products.Pursuant to ... Finest(TM) in several facets of the company,s growth plans, ...
... for 11:00 a.m. ET POWAY, Calif., Jan. 22 ... provider of diagnostic imaging products and services that improve ... before the market opens on Thursday, February 5, 2009, ... December 31, 2008. A conference call is scheduled for ...
Cached Medicine News:Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 2Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 3Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 3Health News:CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy 2Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: